Introduction: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.
Case Representation: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.
Discussion: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.
Conclusion: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0109298673272183240108093135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inferior Outcomes of Fludarabine-Cyclophosphamide-Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia.
Biomedicines
January 2025
Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
: Anti-CD20 monoclonal antibodies combined with alkylator-based chemotherapy enhance survival in chronic lymphocytic leukemia (CLL). However, the risks of infection and bone marrow suppression may mean that new, targeted therapies are more appropriate for some patients than fludarabine-cyclophosphamide-rituximab (FCR). In the Republic of Korea, where insurance limits coverage to novel agents, FCR therapy should be carefully considered for patients with CLL.
View Article and Find Full Text PDFCOST-EFFECTIVENESS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS IN GEORGIA.
Georgian Med News
November 2024
Aim: This study aims to assess the cost-effectiveness of treatment with biological drugs-specifically infliximab, adalimumab, and rituximab-both as monotherapy and in combination therapy for patients with rheumatoid arthritis. Additionally, we will identify the factors that influence this process.
Materials And Methods: A total of 60 patients with moderate to severe rheumatoid arthritis (DAS28 > 3.
Aim: The aim of the study is to determine the effect of anti-inflammatory biological drugs (adalimumab, infliximab and rituximab) on the cardiovascular system during the treatment of patients with rheumatoid arthritis.
Methods: Involved in research 70 women aged 18 to 60 years with a confirmed diagnosis of rheumatoid arthritis (diagnosis confirmed by the American College of Rheumatology 2010 (ACR) and European League of Rheumatology (EULAR) classification criteria). Patients on standard treatment and biological drugs were divided into 3 groups, and the third group was divided into two subgroups.
Follicular lymphoma (FL) outcomes are heavily influenced by host immune activity with immune anti-tumor activity mitigated by PD-1/PD-L1 pathway engagement. Combination CD20-directed therapy plus PD-1 inhibition (PD-1i) increases T-cell tumor killing and NK-cell antibody-dependent cell cytotoxicity (ADCC). Mounting evidence supports immune-priming using PD-1i before cancer-directed agents.
View Article and Find Full Text PDFBaseline [F]FDG PET/CT radiomics for predicting interim efficacy in follicular lymphoma treated with first-line R-CHOP.
BMC Cancer
January 2025
PET/CT center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, Henan, 450008, China.
Objective: To investigate the predictive value of machine learning-based PET/CT radiomics and clinical risk factors in predicting interim efficacy in patients with follicular lymphoma (FL).
Methods: This study retrospectively analyzed data from 97 patients with FL diagnosed via histopathological examination between July 2012 and November 2023. Lesion segmentation was performed using LIFEx software, and radiomics features were extracted through the uAI Research Portal (uRP) platform, including first-order features, shape features, and texture features.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!